

Ligand-free Iron/Copper Cocatalyzed N-Arylations of Aryl Halides with Amines under Microwave Irradiation

Diliang Guo,^{a,b} He Huang,^b Yu Zhou,^b Jinyi Xu,^a Hualiang Jiang,^b Kaixian Chen,^{a,b} and Hong Liu^{*,a,b}

^a Department of Medicinal Chemistry, China Pharmaceutical University, 24

TongjiaXiang, Nanjing 210009, China

^b Drug Discovery and Design Centre, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, and Graduate School, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China

Fax: +86-21-50807088. E-mail: hliu@mail.shcnc.ac.cn.

Contents

General Information	S3
General procedure for the Coupling reaction	S3
Spectroscopic and Analytical Data	S4
Copies of ^1H NMR and ^{13}C NMR of Compounds	S14


General Information

The reagents (chemicals) were purchased from commercial chemical reagent company, and used without further purification unless otherwise stated. All of the microwave-assistant reactions were performed in an InitiatorTM EXP microwave system (Biotage, Inc.) at the specified temperature using the standard mode of operation. Analytical thin-layer chromatography (TLC) was HSGF 254. All products were characterized by their NMR and LRMS and HRMS spectra. Chemical shifts were reported in parts per million (ppm, δ) downfield from tetramethylsilane. Proton coupling patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m) and broad (br).

General procedure for the Coupling reaction: A mixture of Fe₂O₃ (32 mg, 0.2 mmol), Cu(acac)₂ (26 mg, 0.1 mmol), and Cs₂CO₃ (650 mg, 2.0 mmol) was dissolved in DMSO(3 mL). Subsequently, iodobenzene (160 μ L, 1.5 mmol), morpholine (88 μ L, 1.0 mmol) and H₂O (3 mL) were added to this mixture. The vial was sealed and the mixture was then irradiated for 30 min at 150 °C. The mixture was then cooled to room temperature, and diluted with dichloromethane, washed with brine, dried over using anhydrous Na₂SO₄, and concentrated in vacuum. The residue was purified by flash column chromatography (petroleum ether/ethyl acetate = 10 : 1) to yield the expected product **1g** (135 mg, 83%yield). The identity and purity of the product was confirmed by ¹H and ¹³C NMR spectroscopic analysis.

Spectroscopic and Analytical Data

N-butylbenzenamine (**1a**)




¹H NMR (300 MHz, CDCl₃): δ 7.19-7.14 (m, 2H), 6.70-6.66 (m, 1H), 6.61-6.58 (m, 2H), 3.12-3.07 (m, 2H), 1.61-1.54 (m, 2H), 1.46-1.38 (m, 2H), 0.98-0.93 (m, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 148.4, 129.1, 117.0, 112.6, 43.6, 31.6, 20.2, 13.8.

MS (EI, m/z): 149 [M]⁺; HRMS (EI): Calcd. for C₁₀H₁₅N [M]⁺: 149.1204; Found: 149.1208.

N-(2-methoxyethyl)benzenamine (**1b**)




¹H NMR (300 MHz, CDCl₃): δ 7.20-7.15 (m, 2H), 6.74-6.69 (m, 1H), 6.64-6.61 (m, 2H), 3.58 (t, J=5.1 Hz, 2H), 3.37 (s, 3H), 3.27 (t, J=5.1 Hz, 2H).

¹³C NMR (100 MHz, CDCl₃): δ 148.1, 129.1, 117.5, 113.0, 70.9, 58.6, 43.3.

MS (EI, m/z): 151 [M]⁺; HRMS (EI): Calcd. for C₉H₁₃NO [M]⁺: 151.0997; Found: 151.0990.

N-(3-methoxypropyl)benzenamine (**1c**)




¹H NMR (300 MHz, CDCl₃): δ 7.19-7.14 (m, 2H), 6.71-6.66 (m, 1H), 6.62-6.59 (m, 2H), 3.50 (t, J=6.0 Hz, 2H), 3.35 (s, 3H), 3.21 (t, J=6.0 Hz, 2H), 1.91-1.83 (m, 2H).

¹³C NMR (100 MHz, CDCl₃): δ 148.4, 129.1, 117.0, 112.6, 71.1, 58.6, 41.6, 29.2.

MS (EI, m/z): 165 [M]⁺; HRMS (EI): Calcd. for C₁₀H₁₅NO [M]⁺: 165.1154; Found: 165.1149.

N-(cyclopropylmethyl)benzenamine (1d)




¹H NMR (300 MHz, CDCl₃): δ 7.19-7.14 (m, 2H), 6.71-6.66 (m, 1H), 6.61-6.58 (m, 2H), 2.94 (d, J=6.3Hz, 2H), 1.11-1.06 (m, 1H), 0.57-0.51 (m, 2H), 0.25-0.20 (m, 2H).

¹³C NMR (100 MHz, CDCl₃): δ 148.4, 129.2, 117.2, 112.7, 49.0, 10.8, 3.4.

MS (EI, m/z): 147 [M]⁺; HRMS (EI): Calcd. for C₁₀H₁₃N [M]⁺: 147.1048; Found: 147.1044.

N-cyclohexylbenzenamine (1e)




¹H NMR (300 MHz, CDCl₃): δ 7.18-7.12 (m, 2H), 6.68-6.63 (m, 1H), 6.59-6.56 (m, 2H), 3.29-3.21 (m, 1H), 2.08-2.03 (m, 2H), 1.79-1.72 (m, 2H), 1.68-1.62 (m, 1H), 1.44-1.08 (m, 5H).

¹³C NMR (100 MHz, CDCl₃): δ 147.3, 129.2, 116.8, 113.1, 51.6, 33.4, 25.9, 25.0.

MS (EI, m/z): 175 [M]⁺; HRMS (EI): Calcd. for C₁₂H₁₇N [M]⁺: 175.1361; Found: 175.1362.

N-phenylpiperidine (1f)




¹H NMR (300 MHz, CDCl₃): δ 7.26-7.21 (m, 2H), 6.94-6.92 (m, 2H), 6.83-6.78 (m, 1H), 3.14 (t, *J*=5.7 Hz, 4H), 1.74-1.66 (m, 4H), 1.59-1.54 (m, 2H).

¹³C NMR (100 MHz, CDCl₃): δ 152.2, 128.9, 119.2, 116.5, 50.6, 25.8, 24.2.

MS (EI, m/z): 161 [M]⁺; HRMS (EI): Calcd. for C₁₁H₁₅N [M]⁺: 161.1204; Found: 161.1201.

4-phenylmorpholine (1g)




¹H NMR (300 MHz, CDCl₃): δ 7.30-7.25 (m, 2H), 6.92-6.85 (m, 3H), 3.85 (t, *J*=4.8 Hz, 4H), 3.14 (t, *J*=4.8 Hz, 4H).

¹³C NMR (100 MHz, CDCl₃): δ 151.2, 129.1, 120.0, 115.6, 66.9, 49.3.

MS (EI, m/z): 163 [M]⁺; HRMS (EI): Calcd. for C₁₀H₁₃NO [M]⁺: 163.0997; Found: 163.0995.

N-benzylbenzenamine (1h)




¹H NMR (300 MHz, CDCl₃): δ 7.34-7.24 (m, 5H), 7.18-7.12 (m, 2H), 6.73-6.68 (m, 1H), 6.61-6.58 (m, 2H), 4.27 (s, 2H).

¹³C NMR (100 MHz, CDCl₃): δ 148.0, 139.3, 129.2, 128.6, 127.4, 127.1, 117.5, 112.8, 48.2.

MS (EI, m/z): 183 [M]⁺; HRMS (EI): Calcd. for C₁₃H₁₃N [M]⁺: 183.1048; Found: 183.1090.

N-phenethylbenzenamine (1i)




^1H NMR (300 MHz, CDCl_3): δ 7.35-7.30 (m, 2H), 7.26-7.15 (m, 5H), 6.75-6.69 (m, 1H), 6.61-6.59 (m, 2H), 3.40 (t, $J=6.9$ Hz, 2H), 2.91 (t, $J=6.9$ Hz, 2H).

^{13}C NMR (100 MHz, CDCl_3): δ 147.9, 139.2, 129.2, 128.7, 128.5, 126.4, 117.4, 112.9, 45.0, 35.4.

MS (EI, m/z): 197 [M] $^+$; HRMS (EI): Calcd. for $\text{C}_{14}\text{H}_{15}\text{N}$ [M] $^+$: 197.1204; Found: 197.1218.

1-phenyl-1H-pyrazole (1j)




^1H NMR (300 MHz, CDCl_3): δ 7.92-7.91 (m, 1H), 7.74-7.69 (m, 3H), 7.48-7.42 (m, 2H), 7.31-7.26 (m, 1H), 6.47-6.45 (m, 1H).

^{13}C NMR (100 MHz, CDCl_3): δ 141.0, 140.0, 129.3, 126.6, 126.3, 119.0, 107.4.

MS (EI, m/z): 144 [M] $^+$; HRMS (EI): Calcd. for $\text{C}_9\text{H}_8\text{N}_2$ [M] $^+$: 144.0687; Found: 144.0691.

1-phenyl-1H-indole (1k)




^1H NMR (300 MHz, CDCl_3): δ 7.70-7.67 (m, 1H), 7.57-7.54 (m, 1H), 7.49-7.46 (m, 4H), 7.34-7.30 (m, 2H), 7.24-7.14 (m, 2H), 6.67-6.66 (m, 1H).

^{13}C NMR (100 MHz, CDCl_3): δ 139.8, 135.8, 129.5, 129.3, 127.9, 126.4, 124.3, 122.3,

121.1, 120.3, 110.4, 103.5.

MS (EI, m/z): 193 [M]⁺; HRMS (EI): Calcd. for C₁₄H₁₁N [M]⁺: 193.0891; Found: 193.0886.

4-methoxy-N-phenylaniline (1l)




¹H NMR (300 MHz, CDCl₃): δ 7.23-7.19 (m, 2H), 7.08-7.06 (m, 2H), 6.91-6.81 (m, 5H), 5.49 (s, br, 1H), 3.70 (s, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 155.2, 145.1, 135.7, 129.3, 122.1, 119.5, 115.6, 114.6, 55.5.

MS (EI, m/z): 199 [M]⁺; HRMS (EI): Calcd. for C₁₃H₁₃NO [M]⁺: 199.0997; Found: 199.0999.

Diphenylamine (1m)




¹H NMR (300 MHz, CDCl₃): δ 7.29-7.25 (m, 4H), 7.08-7.06 (m, 4H), 6.96-6.91 (m, 2H).

¹³C NMR (100 MHz, CDCl₃): δ 143.0, 129.3, 121.0, 117.8.

MS (EI, m/z): 169 [M]⁺; HRMS (EI): Calcd. for C₁₂H₁₁N [M]⁺: 169.0891; Found: 169.0886.

4-(4-methoxyphenyl)morpholine (2a)




¹H NMR (300 MHz, CDCl₃): δ 6.91-6.83 (m, 4H), 3.87-3.84 (m, 4H), 3.77 (s, 3H),

3.07-3.04 (m, 4H).

^{13}C NMR (100 MHz, CDCl_3): δ 153.9, 145.5, 117.8, 114.5, 67.0, 55.5, 50.8.

MS (EI, m/z): 193 [M] $^+$; HRMS (EI): Calcd. for $\text{C}_{11}\text{H}_{15}\text{NO}_2$ [M] $^+$: 193.1103; Found: 193.1108.

4-(3-methoxyphenyl)morpholine (2b)




^1H NMR (300 MHz, CDCl_3): δ 7.23-7.17 (m, 1H), 6.56-6.52 (m, 1H), 6.47-6.44 (m, 2H), 3.85 (t, $J=4.8$ Hz, 4H), 3.80 (s, 3H), 3.15 (t, $J=4.8$ Hz, 4H).

^{13}C NMR (100 MHz, CDCl_3): δ 160.5, 152.6, 129.8, 108.3, 104.6, 102.1, 66.7, 55.0, 49.1.

MS (EI, m/z): 193 [M] $^+$; HRMS (EI): Calcd. for $\text{C}_{11}\text{H}_{15}\text{NO}_2$ [M] $^+$: 193.1103; Found: 193.1105.

4-(2-methoxyphenyl)morpholine (2c)




^1H NMR (300 MHz, CDCl_3): δ 7.03-6.99 (m, 1H), 6.94-6.92 (m, 2H), 6.89-6.86 (m, 1H), 3.89 (t, $J=4.8$ Hz, 4H), 3.86 (s, 3H), 3.07 (t, $J=4.8$ Hz, 4H).

^{13}C NMR (100 MHz, CDCl_3): δ 152.1, 141.0, 123.1, 120.9, 117.9, 111.1, 67.1, 55.2, 51.1.

MS (EI, m/z): 193 [M] $^+$; HRMS (EI): Calcd. for $\text{C}_{11}\text{H}_{15}\text{NO}_2$ [M] $^+$: 193.1103; Found: 193.1110.

4-p-tolylmorpholine (2d)




¹H NMR (300 MHz, CDCl₃): δ 7.21-7.19 (m, 2H), 7.05-7.02 (m, 2H), 3.87 (t, *J*=4.5 Hz, 4H), 2.93 (t, *J*=4.5 Hz, 4H), 2.33 (s, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 153.4, 148.8, 130.0, 129.6, 116.3, 115.1, 66.8, 50.1, 20.4.

MS (EI, m/z): 177 [M]⁺; HRMS (EI): Calcd. for C₁₁H₁₅NO [M]⁺: 177.1154; Found: 177.1158.

4-m-tolylmorpholine (2e)




¹H NMR (300 MHz, CDCl₃): δ 7.20-7.17 (m, 1H), 6.77-6.73 (m, 3H), 3.89-3.86 (m, 4H), 3.19-3.16 (m, 4H), 2.35 (s, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 151.2, 138.8, 128.9, 120.9, 116.5, 112.8, 66.8, 49.4, 21.7.

MS (EI, m/z): 177 [M]⁺; HRMS (EI): Calcd. for C₁₁H₁₅NO [M]⁺: 177.1154; Found: 177.1151.

4-(4-(trifluoromethyl)phenyl)morpholine (2g)




¹H NMR (300 MHz, CDCl₃): δ 7.50 (d, *J*=6.6 Hz, 2H), 6.92 (d, *J*=6.6 Hz, 2H), 3.87 (t, *J*=3.6 Hz, 4H), 3.24 (t, *J*=3.6 Hz, 4H).

¹³C NMR (100 MHz, CDCl₃): δ 153.3, 126.5, 126.4, 114.3, 66.6, 48.1.

MS (EI, m/z): 231 [M]⁺; HRMS (EI): Calcd. for C₁₁H₁₂F₃NO [M]⁺: 231.0871; Found: 231.0871.

4-(3-(trifluoromethyl)phenyl)morpholine (2h)




¹H NMR (300 MHz, CDCl₃): δ 7.39-7.33 (m, 1H), 7.17-7.11 (m, 2H), 7.08-7.05 (m, 1H), 3.91-3.88 (m, 4H), 3.22-3.20 (m, 4H).

¹³C NMR (100 MHz, CDCl₃): δ 151.4, 129.6, 118.4, 116.3, 116.2, 111.9, 111.8, 66.7, 48.8.

MS (EI, m/z): 231 [M]⁺; HRMS (EI): Calcd. for C₁₁H₁₂F₃NO [M]⁺: 231.0871; Found: 231.0873.

4-(4-nitrophenyl)morpholine (2j)




¹H NMR (300 MHz, CDCl₃): δ 8.16-8.12 (m, 2H), 6.93-6.90 (m, 1H), 6.84-6.81 (m, 1H), 3.87 (t, J=5.1 Hz, 4H), 2.93 (t, J=5.1 Hz, 4H).

¹³C NMR (100 MHz, CDCl₃): δ 155.0, 138.9, 126.2, 125.9, 115.6, 112.6, 66.3, 47.1.

MS (EI, m/z): 208 [M]⁺; HRMS (EI): Calcd. for C₁₀H₁₂N₂O₃ [M]⁺: 208.0848; Found: 208.0855.

4-(4-chlorophenyl)morpholine (2k)




¹H NMR (300 MHz, CDCl₃): δ 7.23-7.20 (m, 2H), 6.84-6.81 (m 2H), 3.86-3.83 (m, 4H), 3.13-3.09 (m, 4H).

¹³C NMR (100 MHz, CDCl₃): δ 149.8, 129.0, 124.8, 116.8, 66.7, 49.3.

MS (EI, m/z): 197 [M]⁺; HRMS (EI): Calcd. for C₁₀H₁₂ClNO [M]⁺: 197.0607; Found: 197.0610.

Indoline (3a)




¹H NMR (300 MHz, CDCl₃): δ 7.13-7.10 (m, 1H), 7.04-6.98 (m, 1H), 6.73-6.70 (m 1H), 6.68-6.62 (m, 1H), 3.64 (s, br, 1H), 3.52 (t, *J*=8.1 Hz, 2H), 3.01 (t, *J*=8.1 Hz, 2H).

¹³C NMR (100 MHz, CDCl₃): δ 151.4, 129.3, 127.1, 124.5, 118.6, 109.4, 47.2, 29.7.

MS (EI, m/z): 119 [M]⁺; HRMS (EI): Calcd. for C₈H₉N [M]⁺: 119.0735; Found: 119.0730.

2-(cyclohexylamino)benzoic acid (3b)




¹H NMR (300 MHz, CDCl₃): δ 7.99-7.96 (m, 1H), 7.38-7.33 (m, 1H), 6.73-6.70 (m 1H), 6.58-6.53 (m, 1H), 3.43-3.42 (d, br, 1H), 2.07-2.02 (m, 3H), 1.80-1.77 (m, 2H), 1.43 (s, 1H), 1.40-1.28 (m, 5H).

¹³C NMR (100 MHz, CDCl₃): δ 174.8, 151.0, 135.4, 132.8, 114.0, 111.8, 108.3, 50.6, 32.8, 25.8, 24.7.

MS (EI, m/z): 219 [M]⁺; HRMS (EI): Calcd. for C₁₃H₁₇NO₂ [M]⁺: 219.1259; Found: 219.1264.

2-methylquinazolin-4(3H)-one (3c)





¹H NMR (300 MHz, DMSO-d₆): δ 12.2 (s, br, 1H), 8.07(d, 1H, *J* = 7.8 Hz), 7.76 (t, 1H, *J* = 7.2 Hz), 7.56 (d, 1H, *J* = 7.8 Hz), 7.44 (t, 1H, *J* = 7.2 Hz), 2.35 (s, 3H).

¹³C NMR (100 MHz, DMSO-d₆): δ 161.7, 154.3, 149.0, 134.2, 126.6, 125.8, 125.7, 120.6, 21.4.


MS (EI, m/z): 160 [M]⁺; HRMS (EI): Calcd. for C₉H₈N₂O [M]⁺: 160.0637; Found: 160.0641.

Copies of ^1H NMR and ^{13}C NMR of Compounds



N-butylbenzenamine (1a)










N-(cyclopropylmethyl)benzenamine (**1d**)






Fe70 CDCL3 BB+DEPT=135 Jul 3 2009












4-phenylmorpholine (1g)







N-benzylbenzenamine (1h)







1-phenyl-1H-pyrazole (1j)










Diphenylamine (1m)





4-(4-methoxyphenyl)morpholine (2a)




FBI GRC13 88+DEPT-135 Jul 15 2009




4-(3-methoxyphenyl)morpholine (2b)









4-p-tolylmorpholine (2d)




4-m-tolylmorpholine (2e)




4-(4-(trifluoromethyl)phenyl)morpholine (2g)




4-(3-(trifluoromethyl)phenyl)morpholine (2h)






4-(4-chlorophenyl)morpholine (2k)



Indoline (3a)



2-(cyclohexylamino)benzoic acid (3b)



2-methylquinazolin-4(3H)-one (3c)

